TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Swedish Orphan Biovitrum AB (publ)
Closing information (x1000 SEK)
| Closing information | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
| Turnover |
18,790,000
|
15,529,000
|
15,261,000 |
| Financial expenses |
497,000
|
454,000
|
602,000 |
| Earnings before taxes |
3,321,000
|
3,295,000
|
4,217,000 |
| EBITDA |
6,087,000
|
5,733,000
|
6,841,000 |
| Total assets |
52,496,000
|
48,661,000
|
48,283,000 |
| Current assets |
11,211,000
|
8,778,000
|
8,168,000 |
| Current liabilities |
14,857,000
|
8,761,000
|
10,443,000 |
| Equity capital |
26,525,000
|
23,203,000
|
20,206,000 |
| - share capital |
170,000
|
169,000
|
167,000 |
| Employees (average) |
1,556
|
1,559
|
1,509 |
Financial ratios
| Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
| Solvency |
50.5%
|
47.7%
|
41.8% |
| Turnover per employee |
12,076
|
9,961
|
10,113 |
| Profit as a percentage of turnover |
17.7%
|
21.2%
|
27.6% |
| Return on assets (ROA) |
7.3%
|
7.7%
|
10.0% |
| Current ratio |
75.5%
|
100.2%
|
78.2% |
| Return on equity (ROE) |
12.5%
|
14.2%
|
20.9% |
| Change turnover |
3,261,000
|
268,000
|
1,013,000 |
| Change turnover % |
21%
|
2%
|
7% |
| Chg. No. of employees |
-3
|
50
|
174 |
| Chg. No. of employees % |
0%
|
3%
|
13% |
Total value of public sale
| Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.